The US government said yesterday that it would provide about USD 11 million to support the packaging of Jynneos monkeypox vaccine at a U.S. based manufacturers facility, as reported by Reuters.
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic which is marketed as IMVANEX in Europe, JYNNEOS in the U.S. and IMVAMUNE in Canada, developed by denmark based Bavarian Nordic. It is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. In addition to smallpox, the U.S. Food and Drug Administration, Health Canada and the European Commission have also approved the vaccine for use against monkeypox as the only vaccine having obtained this to-date.
Recently, Grand River Aseptic Manufacturing, a prominent parenteral drug product contract development and manufacturing organization, has entered into an agreement with a Denmark-based Bavarian Nordic to fill and finish JYNNEOS smallpox/monkeypox vaccine. The agreement was supported by the Department of Health and Human Services and the Biomedical Advance Research and Development Authority to increase domestic vaccine supply.
Previously in July 2022, Bavarian Nordic had received approvals from the U.S. and EU regulatory authorities to manufacture smallpox and monkeypox vaccine at the Company’s fill and finish facility in Denmark.
So far, More than 18000 cases are registered in USA alone. It is well known that Monkeypox can spread to anyone through close, personal, often skin-to-skin contact, including, direct contact with monkeypox rash, scabs, or body fluids from a person with monkeypox; Touching objects, fabrics (clothing, bedding, or towels), and surfaces that have been used by someone with monkeypox; And contact with respiratory secretions.
